Serge Gauthier, Angela Garcia, Mary Sano, Philippe Robert, Vorapun Senanarong, Michael Woodward and Henry Brodaty
Alzheimer`s & Dementia, 2010, 6(4), 359-362. DOI: 10.1016/j.jalz.2010.05.2017
Coordination and harmonization of efforts between five major research consortia on Alzheimers disease may increase our understanding of this condition and improve our therapeutic approaches. Specific opportunities include a registry for families with early onset dementia, a study registry, minimal data sets, validation of assessment tools and outcomes, update on ethical issues, resolution of methodological issues, new investigators training, longitudinal observation studies, prevention studies, and liaison with stakeholders such as Alzheimer Disease International.
ASCI-ID: 285-40
Alzheimer`s & Dementia, 2010, 6(5), 386-393. DOI: 10.1016/j.jalz.2009.12.004
White matter is altered with parental family history of Alzheimers diseaseAlzheimer`s & Dementia, 2010, 6(5), 394-403. DOI: 10.1016/j.jalz.2009.11.003
Influence of apolipoprotein E ε4 on rates of cognitive and functional decline in mild cognitive impairmentAlzheimer`s & Dementia, 2010, 6(5), 412-419. DOI: 10.1016/j.jalz.2009.12.003
Update on the Magnetic Resonance Imaging core of the Alzheimers Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2010, 6(3), 212-220. DOI: 10.1016/j.jalz.2010.03.004
Update on the biomarker core of the Alzheimers Disease Neuroimaging Initiative subjectsAlzheimer`s & Dementia, 2010, 6(3), 230-238. DOI: 10.1016/j.jalz.2010.03.008
Clinical core of the Alzheimers disease neuroimaging initiative: Progress and plansAlzheimer`s & Dementia, 2010, 6(3), 239-246. DOI: 10.1016/j.jalz.2010.03.006
The informatics core of the Alzheimers Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2010, 6(3), 247-256. DOI: 10.1016/j.jalz.2010.03.001
The Alzheimers Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomesAlzheimer`s & Dementia, 2010, 6(3), 257-264. DOI: 10.1016/j.jalz.2010.03.002
Temporal lobe functional activity and connectivity in young adult APOE ε4 carriersAlzheimer`s & Dementia, 2010, 6(4), 303-311. DOI: 10.1016/j.jalz.2009.07.003
The Alzheimers Disease Neuroimaging Initiative: Progress report and future plansAlzheimer`s & Dementia, 2010, 6(3), 202-211. DOI: 10.1016/j.jalz.2010.03.007
Alzheimers Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plansAlzheimer`s & Dementia, 2010, 6(3), 265-273. DOI: 10.1016/j.jalz.2010.03.013
Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: The essential role of the Neuropathology CoreAlzheimer`s & Dementia, 2010, 6(3), 274-279. DOI: 10.1016/j.jalz.2010.03.012
Alzheimers Disease Neuroimaging Initiative in EuropeAlzheimer`s & Dementia, 2010, 6(3), 280-285. DOI: 10.1016/j.jalz.2010.03.005
The Alzheimers Disease Neuroimaging Initiative: Perspectives of the Industry Scientific Advisory BoardAlzheimer`s & Dementia, 2010, 6(3), 286-290. DOI: 10.1016/j.jalz.2010.03.010
Addressing population aging and Alzheimers disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimers Disease Neuroimaging InitiativeAlzheimer`s & Dementia, 2010, 6(3), 291-296. DOI: 10.1016/j.jalz.2010.03.009
Japanese Alzheimers Disease Neuroimaging Initiative: Present status and futureAlzheimer`s & Dementia, 2010, 6(3), 297-299. DOI: 10.1016/j.jalz.2010.03.011
An examination of Alzheimers disease case definitions using Medicare claims and survey dataAlzheimer`s & Dementia, 2010, 6(4), 334-341. DOI: 10.1016/j.jalz.2009.09.001
Deliberative assessment of surrogate consent in dementia researchAlzheimer`s & Dementia, 2010, 6(4), 342-350. DOI: 10.1016/j.jalz.2009.06.001
Improving Alzheimers disease phase II clinical trialsAlzheimer`s & Dementia, 2013, 9(1), 39-49. DOI: 10.1016/j.jalz.2012.02.002